



Södertälje, Sweden, December 8, 1998

**NEW AGREEMENT BETWEEN ASTRA AND SCHERING-PLOUGH
REGARDING RIGHTS TO IMDUR® IN THE U.S.**

For some time Schering-Plough has been marketing the drug isosorbide-5-mononitrate, with the trademark Imdur, in the U.S. market under license from Astra. The product is used in the treatment of angina pectoris. This agreement was valid until 2004. A new agreement has now been reached which entails that Schering-Plough will receive an extension and broadening of the marketing rights to isosorbide-5-mononitrate in the U.S.

Contact persons:

Staffan Ternby, Vice President, PR & Information, Astra AB, +46 8 553 261 07

Mikael Widell, Press Officer, PR & Information, Astra AB, +46 8 553 264 28

Michael Olsson, Manager, Investor Relations, Astra AB, +46 8 553 259 52

Jörgen Winroth, Investor Relations U.S., Astra AB, +1 609 896 4148